摘要
目的探讨胸腺五肽联合左氧氟沙星治疗肺结核的临床疗效及对免疫功能的影响。方法将医院传染病科2015年3月至2017年3月收治的肺结核患者123例随机分为A组(61例)和B组(62例)。A组患者入院后给予常规2HRZE/4HR抗结核治疗,B组患者在此基础上加用胸腺五肽联合左氧氟沙星治疗。结果治疗后,两组患者的临床症状改善比例均显著低于治疗前(P <0. 05),B组高于A组,但差异不显著(P> 0. 05); B组患者在治疗3,6,9个月后痰菌转阴率均高于A组(P <0. 05); B组总有效率为87. 10%,明显高于A组的65. 57%(χ2=19. 753,P <0. 05);治疗后,两组患者的CD3+,CD4+,CD4+/CD8+均明显上升,且B组较A组变化显著(P <0. 05);两组患者的CD8+水平均降低,且B组较A组变化显著(P <0. 05);两组不良反应发生率比较,差异无统计学意义(P> 0. 05)。结论胸腺五肽联合左氧氟沙星治疗肺结核的疗效显著,可显著改善患者免疫功能,安全性高,是一种治疗肺结核的优化选择,值得推广。
Objective To investigate the clinical effect of thymopentin combined with levofloxacin in the treatment of pulmonary tuberculosis and its effect on immune function. Methods Totally 123 patients with pulmonary tuberculosis admitted to the Department of Infectious Disease in our hospital from March 2015 to March 2017 were randomly divided into group A（61 cases） and group B（62 cases）.The patients in group A received routine 2HRZE/4HR anti-tuberculosis treatment after admission, and the patients in group B were treated with thymopentin combined with levofloxacin on the basis of group A. Results After treatment, the improvement rates of clinical symptoms in the two groups were significantly lower than those before treatment（P 〈 0. 05）, and that in group B was higher than that in group A, but the dift）rence was not significant（ P 〉 0.05）. The sputum negative conversion rates of group B were higher than those of group A at 3, 6 and 9 months during the treatment（P 〈 0.05）. The total effective rate of group B was 87. 10%, which was significantly higher than 65.57% of group A（X^2 = 19. 753, P 〈 0. 05）. After treatment, the levels of CD3^＋, CD4^＋, CD4^＋/CD8^＋ in the two groups were significantly increased, and the changes in group B were more significant than those in group A（P 〈 0. 05）. The levels of CD8^＋ in the two groups were significantly decreased, and the change in group B was more significant than that in group A（ P 〈 0.05）. There was no significant difference in the incidence rate of adverse reactions between the two groups（P 〉 0.05）. Conclusion Thymopentin combined with levofloxacin is effective and safe in the treatment of pulmonary tuberculosis, it can significantly improve the immune function of patients, and it is an optimal choice for the treatment of pulmonary tuberculosis, which is worthy of promotion.
作者
范良伟
朱红波
Fan Liangwei;Zhu Hongbo(Wuhan Red Cross Hospital,Wuhan,Hubei,China 43000)
出处
《中国药业》
CAS
2018年第19期28-30,共3页
China Pharmaceuticals
基金
湖北省自然科学基金面上项目[2016CFB378]
关键词
胸腺五肽
左氧氟沙星
肺结核
免疫功能
thymopentin
levofloxacin
pulmonary tuberculosis
immune function
